Australia pays $312 million to use Next-Gen mRNA technology from US

‘CSL says it is paying $US200 million ($A312m) up-front to license next-generation mRNA vaccine technology from a small US company.

CSL said on Wednesday its CSL Seqirus subsidiary, the second-biggest flu vaccine manufacturer globally, has licensed the technology from NASDAQ-listed Arcturus Therapeutics.

We are primarily funded by readers. Please subscribe and donate to support us!

The $US485m NASDAQ-listed company would be eligible to receive more than $US4.3 billion ($A6.7 billion) in milestone payments, plus double-digit royalties under the terms of the deal.’


Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.